Silex Systems

Phase A — Understand the business

Lens 1 · Company Overview

The business in plain terms. Silex Systems Limited (est. 1988, HQ Lucas Heights NSW, next to Australia's ANSTO reactor) owns and licenses the SILEX process — Separation of Isotopes by Laser EXcitation — a third-generation, laser-based uranium enrichment technology. Where legacy enrichment uses gaseous diffusion (first-gen) or centrifuges (second-gen, the current global standard: Urenco, Orano, Rosatom, Centrus), SILEX excites U-235-bearing molecules with tuned lasers to separate isotopes in fewer stages — promising, in theory, lower capital and energy cost per SWU (separative work unit) ``.

Silex does not itself operate an enrichment plant. It commercialises SILEX through Global Laser Enrichment LLC (GLE), the exclusive worldwide licensee, in which Silex holds 51% and Cameco 49% . Under the JV, **Silex is the technology lead and licensor; Cameco is the commercial lead** . Silex's income is essentially: modest technology-services/segment revenue (~A$13m) + interest on its cash pile — while the asset (GLE) sits off the revenue line and is equity-accounted, so GLE's development losses flow into Silex's net loss but GLE's revenue does not flow into Silex's revenue.

Key products / lines.

• SILEX uranium enrichment (the whole thesis) → commercialised via GLE. Flagship project: the Paducah Laser Enrichment Facility (PLEF), Kentucky.
• Quantum Silicon (Q-Si / "Zero-Spin Silicon", isotopically pure Si-28) — the same laser-isotope-separation platform applied to silicon for silicon-based quantum computing. Q-Si production plant completed in Sydney; sample production guided to Q1 CY2027, initial module ~20 kg/yr, targeting a sub-50 kg high-value market ``.
• Medical Isotopes (MIST project, Lucas Heights) — enriching Ytterbium-176, precursor to Lutetium-177 radiopharmaceuticals for advanced cancer (the Novartis Pluvicto class) ``.
• Translucent Inc (cREO — crystalline Rare-Earth Oxides) — legacy semiconductor-materials IP; ~A$2.1m segment revenue, largely a licensing tail ``.

Customers / contract structure. The one contract that matters is GLE's 2016 agreement with the US Department of Energy to acquire the DOE's >200,000 tonnes of high-assay depleted-uranium (DUF6) tails stored at Paducah and re-enrich them to natural-grade uranium at PLEF ``. This is an unusual, favourable feed arrangement: GLE gets a cheap, government-held feedstock rather than buying natural uranium. There are no disclosed commercial LEU/HALEU offtake contracts yet — PLEF output would be sold into the enrichment/uranium market once operating (≈2030). So the "customer base" today is one government feed deal plus a policy tailwind, not a book of utility offtake.

Competitors. Uranium enrichment incumbents: Urenco (only current US commercial enricher, ~4.3m SWU/yr), Orano (Project IKE, licensed for ~7.4m SWU/yr), Centrus (LEU) (American Centrifuge, already producing HALEU), Rosatom/TENEX (the displaced ~44%-of-global incumbent), and the venture-backed newcomer General Matter ``.

Lens 2 · Supply Chain

Map (name the actual nodes):

Feedstock → US DOE (owner of the Paducah DUF₆ tails, ~200,000 t) → GLE (re-enrichment) ``. This inverts the normal fuel chain: instead of buying natural U from miners, GLE's lead project upgrades government waste tails. Single-source, but the source is the US government under a signed 2016 contract — low commercial-counterparty risk, high political dependency.

Technology/IP → Silex Systems (owns SILEX, classified) → licenses GLE (exclusive worldwide) → GLE builds/operates. Silex is the sole source of the enrichment IP; there is no alternate licensor. ``

Capital/commercial → Cameco (49% owner, commercial lead, $40bn+ major, deep uranium-market and utility relationships) is the de-facto route-to-market and the balance-sheet partner. ``

Downstream (once operating, ≈2030) → PLEF LEU output → nuclear fuel fabricators → US/global utilities and, for any HALEU, advanced-reactor developers (SMR/microreactor: TerraPower, X-energy et al.). Output framed as ~6m SWU/yr nominal capacity and ~5m lb U₃O₈-equivalent/yr — "a top-10 uranium mine" ``.

Test-Loop / demonstration node → GLE's Test Loop facility in Wilmington, North Carolina (inherited from the GE-Hitachi era) is where large-scale demonstration ran May–Sep 2025 and where TRL-6 was validated Oct 2025 ``.

Chokepoints / single-source dependencies. (1) The IP is a single point — SILEX is one classified process held by one small Australian company; (2) the feed is a single government contract; (3) the capital is effectively single-sourced to Cameco given Silex's own balance sheet cannot fund a US$1.76bn build; (4) specialised laser systems / precision optics and enrichment-grade engineering are niche supply chains, though not disclosed as constraints. This lens is concentrated by design — that concentration is both the moat and the fragility.

Lens 3 · Competitive Advantages (moats)

The moat is real but narrow, and it is a technology-and-secrecy moat, not a market-power moat.

• Classified, hard-to-replicate IP. SILEX is the only third-generation (laser) enrichment technology demonstrated at large scale (TRL-6) — GLE is "the only company in the world" to have done so ``. The process detail is classified under US and Australian nonproliferation controls, which raises the replication barrier enormously (you cannot simply read the patents). ~35+ years and hundreds of millions of dollars of development sit behind it.
• Feed-cost edge. The DOE tails deal gives GLE a differentiated, low-cost feedstock most enrichers don't have.
• Theoretical cost curve. If SILEX's lower-stage-count promise holds at commercial scale, GLE could sit at the low end of the SWU cost curve — the classic disruptor set-up.

Where the moat is weak.

• Bargaining power is inverted. Silex needs Cameco (capital, market access) far more than Cameco needs Silex — Cameco holds a 49% stake plus an option to 75% it can exercise if Silex fails to fund ``. That is the opposite of pricing power over a partner.
• Not yet proven at commercial scale. TRL-6 is pilot/relevant-environment demonstration, not a running plant (TRL-9). Second-gen centrifuge rivals are already producing (Centrus HALEU; Urenco commercial SWU). A moat that hasn't shipped a commercial SWU is a moat on paper.
• No switching costs / network effects / brand in the consumer sense — enrichment is a commodity (SWU) business; the only durable edge is cost per SWU, which is unproven for GLE.

Verdict on the moat: a deep but singular technology/secrecy moat with essentially zero commercial-scale proof and negative partner-bargaining-power. It protects the idea well; it does not yet protect cash flows, because there are none.

Lens 4 · Segments

No segments.csv on disk (empty) → all ``, FY2025 (year to 30 Jun 2025):

Trend / cause: operating revenue is drifting down at the half-year (H1 FY26 total revenue A$5.8m vs A$7.9m H1 FY25 ``) — this is a pre-commercial R&D company, so revenue direction is noise; the signal is spend on GLE + Q-Si/MIST, not top-line.

---

Phase B — Measure performance

Adapted: no positive P&L exists, so these lenses read the milestone stack, the balance sheet, and the tape.

Lens 5 · Earnings Result (latest print: H1 FY2026, to 31 Dec 2025, reported 24 Feb 2026)

• Total revenue A$5.8m, net loss A$24.5m, basic EPS −A$0.10 ``. Revenue fell from A$7.9m (H1 FY25).
• FY2025 full year (to 30 Jun 2025): net loss ~A$42.6m (EPS −A$0.18), of which ~A$41.7m was Silex's equity share of GLE's development-phase losses ``. This is the single most important accounting fact in the file: the loss is not operational bleeding — it is capitalised-in-substance investment in the GLE asset, run through the P&L via equity accounting. A rising "loss" here is, perversely, a sign of more GLE spend, i.e. progress toward FID.
• Balance sheet — the genuine strength. Post the August 2025 A$130m institutional placement (~33.3m shares @ A$3.90) plus an SPP, Silex guided to ~A$214.6m cash and "fully funded through end-FY28"; net debt negligible (~A$0.9m) . Pre-raise cash was ~A$69.6m. By mid-2026, cash is being drawn down to fund GLE — current cash ≈ **A$170–190m** .
• Guidance / tone. No earnings guidance (nothing to guide). Management's "guidance" is the milestone calendar: TRL-6 (done Oct-25), NRC license application (filed Jul-25, accepted), $1.76bn PLEF announced (Mar-26), NRC EIS (~Sep-26), NRC Safety Evaluation Report (~Jan-27), first re-enrichment "no later than 2030, potentially as early as 2028" ``.
• Market reaction — the print is not the catalyst. The stock is driven by DOE/NRC/technology binary events, not the half-year. The dominant recent reaction was to the Jan-2026 DOE award miss (see Lens 8), not to any earnings line.
• Unusual vs its own history: losses are widening as designed (more GLE spend); the anomaly is that the widening loss coincided with the share price falling ~60% across 2026 — the market re-rated the option, not the earnings.

Lens 6 · Earnings Calls / communications (sentiment trend)

No transcripts/ on disk. Silex holds AGMs and investor briefings rather than US-style quarterly calls; sentiment read from releases ``:

• Mid-2025 (TRL-6 build, NRC filing): management tone peak-confident — "the only company in the world" at TRL-6, "confidence the process can be commercially deployed," framing a "multi-billion-dollar opportunity." ``
• Jan 2026 (DOE miss): tone shifts to defensive / "vows to push on." The innovationaus headline — "Silex vows to push on after US$900m contract miss" — captures it ``. Management reframes: the DOE funded the technology (US$28.5m) but chose others for near-term LEU volume; PLEF-via-tails remains the bigger, longer prize.
• Mar 2026 (PLEF $1.76bn + KY incentives + NRC DEIS): tone re-assertive — emphasise "single largest investment in Western Kentucky history," institutional/government support, US$98.9m incentives.
• Recurring phrases: "third-generation," "only TRL-6 laser enricher," "fully funded to FY28," "no later than 2030." Phrase they've gone quiet on: near-term HALEU production and any near-term DOE production revenue — because GLE declined the DOE HALEU RFP and lost the LEU production award ``. The sentiment arc is confidence → defensiveness → re-assertion, tracking exactly the government-validation events.

Lens 7 · Comps

Enrichment/fuel-cycle peers. Multiples are `` with date, or n/a. Silex's own P/E and EV/EBIT are n/a — earnings are negative; EV/Sales is meaningless (~45–65× on ~A$13–18m revenue) and is deliberately not presented as a valuation anchor.

Read. The market pays ~57× earnings for the enricher that ships (Centrus) and a ~US$0.68bn option premium for the enricher that hasn't (Silex). Silex is not comparable to CCJ (large-cap fuel major) on multiples; the honest comps are ASPI (similar pre-scale, ~US$0.64bn — Silex trades at a modest premium on the strength of TRL-6 + the Cameco/DOE relationships) and the private set (General Matter, Urenco, Orano) on strategic position rather than on multiples. You cannot value Silex on a multiple; it is an option, valued in Lens 11.

Lens 8 · Stock-Price Catalysts (>5% moves, 5-yr pattern)

`` throughout. The tape shows this name trades on government/technology binary events + the uranium macro — never on earnings:

• 2023–2024 — the uranium/enrichment bull run + Russian-ban tailwind (Prohibiting Russian Uranium Imports Act, signed May-2024): SLX re-rated from ~A$2–3 toward a multi-A$-billion market cap. Macro-driven.
• Jul 2025: GLE files full NRC license application for PLEF — positive milestone ``.
• Aug 2025: A$130m placement @ A$3.90 — dilution, modest reaction ``.
• Oct 2025: TRL-6 achieved / independently validated → +17% single session, market cap "above A$2bn" ``. The high-water mark of confidence.
• Jan 2026 — THE catalyst: DOE US$900m award MISS. DOE issues first production task orders under its US$2.7bn program: US$900m each to Centrus, General Matter, Orano; GLE gets US$28.5m (HALEU Technologies bucket, not production). SLX plunged ~26–29% in a session (to ~A$6.93 from ~A$9.75), "half a billion dollars wiped off" ``.
• Mar 2026: $1.76bn PLEF formally announced + US$98.9m KY/McCracken incentives + NRC Draft EIS published — positive news that the stock faded: SLX kept sliding to ~A$3.74 by Jul-2026 (down ~60%+ from the pre-Jan level) ``.

What the pattern reveals: the market reacts to who the US government picks and whether the technology clears its next gate — and it has decided, across 2026, that losing near-term production money to centrifuge incumbents + a Thiel-backed startup outweighs winning a bigger-but-later capex commitment. A binary, sentiment-heavy, policy-levered stock. The next binaries are the NRC EIS (Sep-26) and SER (Jan-27).

---

Phase C — Judge people & books

Lens 9 · Management

• Michael Goldsworthy — Founder, MD & CEO since 1992 (~33 years). The scientist who invented SILEX and has carried it from Lucas Heights bench to a licensed, TRL-6, US-government-contracted JV ``. Track record: genuinely built a world-first enrichment technology and — critically — reacquired SILEX/GLE from GE-Hitachi and restructured it into the Silex-majority/Cameco-partner vehicle (2016–2021), which looks prescient given the post-2022 enrichment scramble. That is real, quantified value creation of the strategic-asset kind.
• Tenure & skin in the game. 33-year founder-CEO tenure signals conviction — but direct ownership is only ~0.29% (~A$3.2m) ``, low for a founder. Board tenure averages ~20 years (deep, possibly stale); management ~8.8 years. CFO Julie Russell since 2012 (also Company Secretary). New non-exec (Ms Corlett, Nov-2024) adds mining-finance/investment experience — plausibly a deliberate signal of the coming project-finance phase.
• Capital-allocation history. The signature call — buying back the technology and taking JV control — was excellent. Ongoing allocation is repeated equity raises to fund GLE (share count ~173m FY21 → ~278m now, ~+60%), i.e. dilution is the funding model. No buybacks, no dividend (correct for this stage). ROE/ROIC negative by design. The judgement to watch: do they keep diluting SLX holders, or push the funding burden onto Cameco/GLE-level project finance?
• Red flags. None of the fraud/related-party type surfaced. The honest flags are strategy concentration (near-total bet on GLE, other lines are call-options) and promotional cadence ("only company in the world," "multi-billion-dollar opportunity") that set expectations the Jan-2026 miss then punished.
• Archetype. Founder-scientist, not a professional operator/financier. Superb at inventing and stewarding a classified deep-tech asset; the US$1.76bn project-finance + commercial-ramp phase demands skills (large-scale capital markets, nuclear construction, offtake origination) that historically sit with Cameco, not Silex — which is precisely why Cameco is commercial lead and why Silex's economic share is likely to dilute.

Lens 10 · Forensic Red Flags

No filings on disk; assessment is `` + first-principles on the disclosed structure. The accounting is unusually clean for a company with a huge headline loss — because the loss is honest:

• Revenue recognition: immaterial (~A$13m of tech/grant/licensing); no aggressive top-line to flatter. Low risk.
• Equity-method investment (the key line): GLE is equity-accounted, so ~A$42m of FY25 loss is Silex's share of GLE's development spend, not operating cash burn at the parent. This is conservative/appropriate treatment — but it also means GLE's real balance sheet, funding needs, and any impairment risk are one step removed from Silex's face financials. Watch the carrying value of the GLE investment for impairment if PLEF slips or financing terms turn punitive.
• Cash vs earnings: the parent's cash position is strong and real (~A$170–190m ); FCF was slightly positive (~A$2.9m FY25 ) because the big "loss" is non-cash equity accounting. No divergence between cash and earnings that signals manipulation — the opposite of a red flag.
• Receivables/inventory outrunning revenue: n/a — negligible revenue, no inventory build.
• SBC / dilution: the flatterer here is share issuance, not SBC — the ~+60% share-count growth is the real dilution to model.
• Going concern: not flagged — funded to FY28 ``. The going-concern question returns only when the FY28 runway meets the FID capital call.

Regulatory findings (required sub-section).

• SEC (EDGAR EFTS — LR + AAER): 0 findings. regulatory/regulatory-findings.md (fetched 2026-07-10) confirms Silex has no CIK and cannot be searched in EDGAR — it is an ASX filer, not an SEC registrant ``. (This is the one and only research-layer artifact on disk, and it contains no findings — not a clean bill from EDGAR so much as EDGAR having no jurisdiction.)
• Non-SEC enforcement (web): searched Silex/GLE against FTC/DOJ/fines/penalties/consent-decree/settlement — no material enforcement actions found ``. The NRC relationship is a licensing counterparty, not an enforcement one; the PLEF license is under active, normal-course review.
• The genuine regulatory overhang — proliferation, not fraud. SILEX has a long-standing nonproliferation controversy: the FAS, APS, AAAS and "19 experts" petitioned the NRC (2012, re: the GE-Hitachi Wilmington license) for a fuller proliferation assessment, arguing laser enrichment is uniquely concealable and efficient at making highly-enriched uranium, i.e. a potential proliferation "game changer" ``. The NRC nonetheless licensed the Wilmington facility. The double edge: the same classification that makes SILEX a moat also exposes it to policy/licensing friction and campaign risk. This is a risk to monitor at every NRC gate, not a current legal liability.
• Item 3 (Legal Proceedings): n/a — no 10-K exists (foreign filer, no CIK).
• Summary: No material regulatory or legal enforcement findings — verified via SEC EDGAR EFTS (no CIK/no jurisdiction), web search (FTC/DOJ/etc., nil), as of 2026-07-10. The material regulatory factor is the standing nonproliferation debate around laser enrichment and the live NRC PLEF licensing, not any enforcement action.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (base / bull / bear) — value-inflection, not EPS

Silex has no positive EPS to project and will not for years — through PLEF construction (2026–2030) the parent's reported result stays negative (its equity share of GLE's build + parent opex), and revenue stays immaterial. Projecting a positive 3-year EPS line would be a fabrication. So this lens is run as path-to-value / net-loss-and-milestone, per the pre-commercial reality. (Per task: no forecast.ts create executed. Falsifiable base call stated below for future scoring.)

Inputs (all /): PLEF nominal capacity ~6m SWU/yr; SWU spot ~US$200/SWU (Dec-25→Mar-26) ``; PLEF total capex US$1.76bn; first re-enrichment 2028 (early) / 2030 (base); Silex GLE stake 51%, at risk of diluting toward ~25% if Cameco exercises its 75% option to carry the build.

• Bear (≈A$1.50–2.50): NRC review slips or attaches conditions; PLEF FID delayed past 2028; Silex, unable to fund its 51% pro-rata of ~US$1.76bn against ~A$180m cash, dilutes heavily (Cameco → 75%, and/or repeated SLX equity raises). The option decays with time and dilution; uranium/enrichment sentiment stays soft. ``
• Base (≈A$4.00–5.00): NRC EIS (Sep-26) and SER (~Jan-27) clear on schedule; a Cameco-led project-finance + DOE-loan-guarantee package funds PLEF with Silex contributing a manageable slice (accepting some GLE-level dilution); first re-enrichment ~2029–2030. The option holds and modestly re-rates on de-risking. ``
• Bull (≈A$8–12+): NRC license granted, FID taken, a named LEU/HALEU offtake signed, financing done without crushing Silex's economics; at ~6m SWU/yr and ~US$200/SWU the gross revenue potential of GLE approaches ~US$1bn/yr (top-10-mine-equivalent) , and the market re-rates Silex's 51% toward a producing-enricher multiple (cf. Centrus at ~57× / 7.5× P/S). Analyst consensus (thin, 2 analysts) sits at a **A$11.6 avg 12-mo target** — i.e. the sell-side is anchored to roughly this bull path. ``

Falsifiable base call (for later scoring, not logged): "By 30 Jun 2028 (FY28), Silex will (a) still report a net loss, and (b) either have taken PLEF FID with financing that keeps Silex's GLE economic interest ≥40%, OR have diluted its GLE interest below 40% to Cameco. Base case: FID reached AND Silex ≥40% — p ≈ 0.45." The bet is genuinely binary on (NRC clearance × financing terms).

Lens 12 · Bull vs Bear

Bull case (narrative). Silex owns the only large-scale-demonstrated third-generation enrichment technology on earth, at the exact moment the West is spending US$2.7bn+ of public money to rebuild enrichment capacity it spent 30 years offshoring to Russia. TRL-6 is validated, the NRC clock is running, Cameco ($40bn) is the funding-and-market partner, and the DOE tails deal hands GLE a cheap feedstock nobody else has. The 2026 sell-off confused "didn't win the near-term production cheque" with "technology rejected" — but the DOE funded the tech and PLEF (a bigger, longer prize) is advancing with $98.9m of state incentives and a $1.76bn build. On top sits free platform optionality — Q-Si for quantum computing and Yb-176/Lu-177 medical isotopes — real call-options the market currently ascribes ~zero to. If SILEX ships a commercial SWU at the low end of the cost curve, a ~US$0.68bn option on a would-be top-10-mine-equivalent enricher is cheap.

Bear case (2–3 permanent-impairment risks).

1. The technology never clears commercial scale / NRC economically. TRL-6 ≠ a running plant; laser enrichment has been "5 years away" for two decades. If PLEF stalls or the process doesn't hit its cost promise at scale, the entire option is worth the parent's cash and little else.
2. Silex gets financed out of its own upside. It cannot fund 51% of US$1.76bn. Cameco's 75% option is a loaded spring: the most likely "success" path still dilutes Silex's economic interest and/or the SLX share count materially before first revenue. You can be right on the technology and still see equity value transferred to Cameco/debt.
3. Competition takes the near-term market. Centrus is already producing HALEU and won US$900m; General Matter (Thiel/Founders Fund) won US$900m and sits literally next door in Paducah; Urenco/Orano are expanding licensed capacity now. The 3–4-year Western supply gap may be filled by centrifuges before laser is commercial, leaving GLE a later, smaller slice.

Pre-mortem (18 months on, thesis broke): NRC review dragged into a contested hearing on proliferation grounds; FID slipped to 2029+; Silex ran down its cash and did a dilutive raise at a lower price while Cameco quietly moved toward 75%; Centrus/General Matter announced production milestones; SWU spot softened as inventories were drawn. SLX halved again.

Are multiples too high? There is no multiple — it is an option, and after a ~60% drawdown the option is cheaper than at TRL-6, though still pricing meaningful commercialisation success. Not "too high"; appropriately de-rated for a back-loaded, dilution-exposed binary.

Contrarian view (what the market refuses to see): the 2026 crowd is trading Silex as "the enricher that lost." The overlooked frame: the DOE and Kentucky are still funding GLE, TRL-6 is done, and the tails deal + Cameco make PLEF the West's optionally-cheapest new enrichment — the value was always 2028–2030, and the price now embeds mostly failure and dilution. The market is also giving zero credit to the Si-28/quantum and Lu-177/medical-isotope platform, which are separate, real, high-value laser-isotope applications.

Lens 13 · Devil's Advocate (short-seller)

Where the money breaks: Silex makes money only if a single, unproven-at-scale, classified process clears the NRC and gets financed on terms that leave Silex real equity and beats already-producing centrifuges to a commercial slice — a conjunction of hard, sequential, binary events, each with a real failure branch, none resolving before ~2027–2028.

• Revenue concentration = 100% on one asset (GLE), one project (PLEF), one feed contract (DOE tails). Any single break impairs the whole.
• The moat may be weaker than bulls think: "only TRL-6 laser enricher" is true but circular — no one else pursues laser because centrifuges already work and are cheaper to deploy today. Being the only one doing the hard, unproven thing is not automatically a moat; it can be a negative selection signal, which is arguably what the DOE's award pattern (money to centrifuge players + a $28.5m consolation to GLE) revealed.
• Most dangerous competitor bulls underrate: General Matter. A Thiel/Founders-Fund, ex-SpaceX/Anduril-DNA startup with US$900m of DOE money and In-Q-Tel backing, building next door in Paducah — politically wired, capital-rich, and explicitly framed as "the first privately developed US enrichment facility." It can out-fund and out-lobby a small Australian licensor. ``
• Worst capital-allocation reality: dilution is the business model — and the good outcome (funding PLEF) is itself the mechanism (Cameco's 75% option) by which Silex holders' claim on the prize shrinks.
• Assumptions that must hold for A$3.74: NRC clears on a workable timeline; PLEF gets financed; SILEX hits cost targets at scale; SWU prices stay elevated (~US$200); Silex isn't diluted to the point of irrelevance. Take 20–30% off "growth" (slip FID two years, dilute GLE to ~30%) and fair value compresses toward the A$1.50–2.50 bear zone.
• Single scenario that permanently impairs: the NRC review becomes contested on proliferation grounds (the standing 2012-style campaign reignites) and imposes conditions or delay that push FID past Silex's FY28 funding wall → forced dilutive raise into a soft tape → Cameco carries the build → Silex ends up a ~25% minority in an asset it invented. Plausibility: moderate, not tail — the proliferation critique is dormant, not dead, and the funding gap is arithmetic fact.

Lens 14 · Management Questions (ordered by information value)

1. PLEF is US$1.76bn and Silex holds 51% with ~A$180m of cash — exactly how do you fund your share of FID without either triggering Cameco's move to 75% or a large SLX equity raise? Show the capital stack (equity/GLE-level project debt/DOE loan guarantee/strategic offtake).
2. At FID, what is the realistic range for Silex's residual economic interest in GLE (51% → ?), and at what point does Cameco's 75% option get exercised?
3. What are the binding NRC dates you're underwriting to — EIS (Sep-26), SER (Jan-27), license — and what is your contingency if the mandatory hearing becomes contested on proliferation grounds?
4. The DOE chose Centrus, General Matter and Orano for US$900m production awards and GLE for US$28.5m of technology money. In the DOE's own words, why not GLE for production — and what specifically changes that in the next RFP round?
5. What firm LEU/HALEU offtake (utility or reactor developer) do you have or expect, and by when — i.e. who buys PLEF's ~6m SWU/yr?
6. TRL-6 is pilot scale. What is the concrete, funded path from TRL-6 to a running commercial module (TRL-8/9), and what is the single biggest remaining technical risk?
7. What is GLE's modelled cost per SWU at commercial scale vs Urenco/Orano/Centrus centrifuges — the number that determines whether laser actually wins?
8. Cameco is commercial lead and your largest partner-cum-competitor-for-control. Where do Silex and Cameco interests diverge, and how are they governed?
9. General Matter is building next door in Paducah with US$900m and Thiel/Founders-Fund backing. How does that change PLEF's economics, labour market, and DOE relationship?
10. Cash is guided "fully funded to FY28." What does the funding picture look like in FY29–FY30 through first production, and what raises are already contemplated?
11. Beyond re-enriching DOE tails, what is the standalone commercial case for PLEF (buying natural feed) once the tails run down?
12. Quantum Silicon (Si-28) and Yb-176/Lu-177 medical isotopes — are these fundable and material, or optionality you would divest to concentrate on enrichment? What would you sell them for?
13. Insider ownership is ~0.29%. Will the founder and board increase alignment ahead of the FID decision?
14. What specific milestone in the next 12 months should investors treat as the make-or-break de-risking event?
15. If SILEX is not commercially deploying by 2030, what is Plan B for the technology and for shareholder capital?

---